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1442normal reference population (6,7).
However, no clear consensus ex-
ists regarding the composition of
a “normal population” in this
context (3,5,8). Given the central
role of troponin measurement in
MI diagnosis, accurate determi-
nation of the upper reference limit
is critically important for the use
and interpretation of troponin
assays.page 1449The presently accepted 99th percentile upper reference
limit for the hs-cTnT assay (14 ng/l) was initially derived
from a study of 616 “apparently healthy” volunteers and
blood donors, with little information reported regarding
subject selection (6), and then conﬁrmed by a study of 533
individuals selected based primarily on a standardized
questionnaire (9). Other studies in smaller cohorts, with
varying degrees of phonotypical characterization, reported
99th percentiles ranging from 14.4 to 16.9 ng/l (8,10–12).
Clinical use of the present cutoff for the hs-cTnT assay
does not take into account patient sex, age, and race.
However, sex differences in the 99th percentile values for
both hs-cTnT and high-sensitivity cardiac troponin I
(hs-cTnI) assays have been reported in a number of small
studies (8–15), with a trend for higher values in men,
leading to a statement in the most recent Universal
Deﬁnition of MI that sex-dependent upper reference
limits for high-sensitivity cardiac troponin assays may be
recommended in the future (7). A numeric trend towards
higher 99th percentiles for the high-sensitivity cardiac
troponin assay in older individuals was also reported in
some, but not all studies, based on very few subjects in
older age strata (9,11,13,14). Finally, whether the 99th
percentiles for high-sensitivity cardiac troponin assays are
inﬂuenced by race is unclear. Presently available data are
insufﬁcient to derive sex-, age-, or race-speciﬁc upper
reference limits.
To address this critical knowledge gap, we analyzed
cTnT values measured with the hs-cTnT assay in 3 large
independent community-based cohorts: the DHS (Dallas
Heart Study) study (16), the ARIC (Atherosclerosis Risk
in Communities) study (17), and the CHS (Cardiovascular
Health Study) study (18). We determined 99th percentile
values for the hs-cTnT assay in clearly deﬁned subcohorts
of the DHS, ARIC, and CHS studies, with sequential
exclusion of “nonhealthy” participants and those with
subclinical cardiovascular disease, and with additional
stratiﬁcation by age, sex, and race. Compared with previous
studies of the hs-cTnT assay upper reference limit, the
present study of 12,618 adults beneﬁts from a much larger
size, unambiguous selection process, detailed phenotypiccharacterization, and broader representation of different
age ranges.Methods
Study design and populations. Cross-sectional analyses
were performed in 3 independent community-based cohorts:
the DHS study, the ARIC study, and the CHS study. The
DHS is a probability-based sample of 6,101 adults enrolled
between 2000 and 2002 from Dallas County, Texas, with
intentional oversampling of black individuals to constitute
approximately 50% of the cohort (19). cTnT was measured
in 3,546 DHS study participants between 30 and 65 years
of age. The cohort component of the ARIC study comprises
a total of 15,792 individuals 45 to 64 years of age, randomly
selected from Forsyth County, North Carolina; suburban
Minneapolis, Minnesota; Jackson, Mississippi; and Wash-
ington County, Maryland (approximately one quarter of the
cohort from each region) (20). For the ARIC study, cTnT
was measured during visit 4 of the study (1996 to 1998),
in 11,271 eligible individuals (17). The CHS study is a
sample of 5,888 community-dwelling adults 65 years of
age or older recruited from 4 communities: Forsyth County,
North Carolina; Hagerstown, Maryland; Pittsburgh, Penn-
sylvania; and Sacramento, California (21). Of the CHS
study cohort, 5,201 individuals were enrolled in 1989 to
1990 (main cohort), and 687 additional black subjects were
enrolled in 1992 to 1993 (supplemental cohort). cTnT
was measured in 4,221 participants from the CHS study.
Detailed descriptions of the design, objectives, and ex-
aminations performed for each of the 3 cohort studies
have been previously published (19–21). The study com-
plied with the Declaration of Helsinki, all participants in
the DHS, ARIC, and CHS studies provided written
informed consent, and approval for the study was obtained
from the institutional review boards at all participating
institutions.
Deﬁnition of subcohorts/exclusion criteria. Because the
99th percentile upper reference limit for cTnT is by con-
vention established in a normal reference population (6,7), we
restricted our analyses to 2 prospectively deﬁned subcohorts
selected from each of the 3 studies. Subcohort 1 was deﬁned
as individuals free from recent hospitalization of any cause
(6 months prior to blood collection for the study), with
no clinical cardiovascular disease (coronary heart disease,
chronic heart failure, atrial ﬁbrillation, prior stroke) or stage
III or greater chronic kidney disease (estimated glomerular
ﬁltration rage <60 ml/min/1.73m2). Subcohort 2 further
excluded from subcohort 1 those individuals with subclinical
structural heart disease, deﬁned as left ventricular hyper-
trophy by electrocardiography (ARIC and CHS) or mag-
netic resonance imaging (DHS), left ventricular ejection
fraction<55% by echocardiogram (CHS,ARIC) ormagnetic
resonance imaging (DHS), or N-terminal pro–B-type natri-
uretic peptide (NT-proBNP) >450 ng/l. Subjects with
missing or exhausted biorepository sampleswere also excluded
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1443from both subcohorts, and subjects with missing imaging or
electrocardiography data were excluded from subcohort 2.
Laboratory measurements. cTnT was measured in sam-
ple aliquots previously stored at 70C using a highly
sensitive automated immunoassay (Troponin T hs STAT,
Elecsys-2010, Roche Diagnostics, Indianapolis, Indiana),
with a limit of detection of 5 ng/l and a limit of blank
of 3 ng/l. The lowest cTnT concentration that can be
measured with a coefﬁcient of variation  10% with
this assay is 13 ng/l (22). The assay lot numbers used
were 153401 for the DHS study, 153401 and 154102
for the ARIC study, and 153401 for the CHS study.
None of these lots were affected by problems reported
by the manufacturer with other lot numbers (23,24).
NT-proBNP levels were measured as described (25).
Glomerular ﬁltration rate was estimated using the Modi-
ﬁcation of Diet in Renal Disease formula (26).
Statistical analyses. The 99th percentile values and cor-
responding 95% conﬁdence intervals were calculated
for subcohorts 1 and 2 of the DHS, ARIC, and CHS
studies, with further stratiﬁcation by sex, age and race.
Distribution-free conﬁdence intervals were used because of
the skewed distribution of cTnT. Speciﬁcally, rank order
statistics were used for the bounds on the conﬁdence limit
such that the difference in the cumulative binomial prob-
abilities satisﬁed the coverage probability requirement of
0.95. The 95% conﬁdence interval for a given 99th
percentile indicates that the 99th cTnT percentile of a
general population sample with similar baseline character-
istics as the respective subcohort or sex/age/race stratumTable 1 Baseline Characteristics of the Study Subcohorts
DHS
Subcohort 1*
(n ¼ 2,955)
Subcohort 2y
(n ¼ 1,978)
Age, yrs 43.3 (9.8) 43.2 (9.6)
Female 54.5 55.9
Race/ethnicity
Black 49.4 41.5
White 30.5 36.1
Hispanic/Latino 17.9 20.1
Asian/Paciﬁc Islander 1.9 2.1
Native American 0.3 0.2
Other 0.1 0.1
Smoking 27.8 24.7
Hypertension 29.8 24.4
Diabetes mellitus 9.9 8.3
GFR <90 ml/min/1.73 m2 33.2 35.6
LVH or LVEF <55% 10.3 0
NT-proBNP >450 ng/l 0.8 0
Detectable cTnT (hs-cTnT assay) 23.9 21.1
Values are median (interquartile range) or %. *Subcohort 1: Subjects free from recent hospitalization (6 m
prior stroke), and stage III or greater chronic kidney disease (estimated glomerular ﬁltration rate [GFR] <
cardiovascular disease (coronary heart disease, chronic heart failure, atrial ﬁbrillation, prior stroke), subc
[LVEF] <55% by echo or magnetic resonance imaging, left ventricular hypertrophy by electrocardiography
kidney disease (estimated GFR <60 ml/min/1.73 m2). zIn the ARIC (Atherosclerosis Risk in Communitie
thus Hispanic/Latino subjects self-reported their race separately from their Hispanic/Latino ethnicity.
cTnT ¼ cardiac troponin T; DHS ¼ Dallas Health Study; GFR ¼ glomerular ﬁltration rate; hs-cTnT ¼
hypertrophy; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.has a 95% probability of falling within the calculated
conﬁdence interval. Within the DHS cohort only, sensi-
tivity analyses were performed to determine the impact
of assumptions made in determining the composition of
subcohort 2. In these sensitivity analyses, the impact of
various inclusion/exclusion criteria (including imaging,
electrocardiography, and NT-proBNP criteria) on the 99th
percentile cTnT value was assessed.Results
Characteristics of the study population. Baseline de-
mographic, clinical, and laboratory characteristics of the
study subcohorts are presented in Table 1. A total of 12,618
adults were analyzed across the 3 studies. The median age
was lowest in DHS and highest in CHS.
The 99th percentile values for the hs-cTnT assay. The
99th percentile values for subcohort 1 (representing adults
without clinically overt cardiovascular disease or impaired
renal function) are presented in Table 2 and Figure 1, with
data for subcohort 2 (those additionally free from subclinical
structural heart disease or an elevated NT-proBNP) corre-
spondingly shown in Table 3 and Figure 2. The 99th
percentile values were signiﬁcantly higher than 14 ng/l (95%
conﬁdence intervals do not cross 14 ng/l) in subcohort 1 for
all 3 studies, and in subcohort 2 for all studies except DHS.
Moreover, the 99th percentile values were signiﬁcantly >14
ng/l in all strata of men 50 years and women 65 years.
Importantly, 99th percentile values were consistent across
cohorts within age and sex strata.ARIC CHS
Subcohort 1
(n ¼ 7,788)
Subcohort 2
(n ¼ 7,575)
Subcohort 1
(n ¼ 1,875)
Subcohort 2
(n ¼ 1,374)
61 (9) 61 (9) 73 (6) 72 (6)
61.2 60.8 62.9 64.4
21.1 20.9 18.2 20.6
78.9 79.1 81.5 79.8
N/Az N/A N/Az N/A
0 0 0.1 0.1
0 0 0.1 0.2
0 0 0.1 0.2
12.8 12.8 10.5 10.1
41.6 40.8 53.4 52.3
9.9 9.8 12.4 11.6
20.9 20.7 90.3 89.2
2.42 0 7.7 0
1.1 0 5.4 0
37.9 38.2 56.1 52.3
onths), clinical cardiovascular disease (coronary heart disease, chronic heart failure, atrial ﬁbrillation,
60 ml/min/1.73 m2). ySubcohort 2: Subjects free from recent hospitalization (6 months), clinical
linical cardiovascular disease (left ventricular hypertrophy [LVH] or left ventricular ejection fraction
, N-terminal pro–B-type natriuretic peptide [NT-proBNP] >450 ng/l), and stage III or greater chronic
s) and CHS (Cardiovascular Health Study) studies race and ethnicity were recorded separately, and
high-sensitivity cardiac troponin T; LVEF ¼ left ventricular ejection fraction; LVH ¼ left ventricular
Table 2
The 99th Percentile Values and Corresponding 95% CIs for hs-cTnT and Percentiles Corresponding to cTnT ¼ 14 ng/l in
Subcohorts 1* of the DHS, ARIC, and CHS Studies, With Further Stratiﬁcation by Sex, Age, and Race
DHS ARIC CHS
n
99th hs-cTnT
Percentile
[95% CI] (ng/l)
Percentile
for hs-cTnT
14 ng/l N
99th hs-cTnT
Percentile
[95% CI] (ng/l)
Percentile
for hs-cTnT
14 ng/l n
99th hs-cTnT
Percentile
[95% CI] (ng/l)
Percentile
for hs-cTnT
14 ng/l
Entire subcohort 1 2,955 18 [16–23] 98.3 7,788 22 [20–24] 95.8 1,875 36 [30–42] 90.9
Stratiﬁed by
sex
Men 1,346 23 [19–47] 97.1 3,023 28 [24–35] 91.7 695 39 [34–44] 83.5
Women 1,609 12 [9–18] 99.2 4,765 16 [15–17] 98.4 1,180 34 [24–41] 95.3
Stratiﬁed by sex and
age (yrs)
Men <50 992 19 [14–50] 98.2 0 N/A N/A 0 N/A N/A
Men 50–64 339 28 [23–83] 94.0 2,030 24 [21–31] 93.3 0 N/A N/A
Men 65–74 15 N/A N/A 992 35 [27–49] 88.4 404 36 [28–59] 87.5
Men 75 0 N/A N/A 1 N/A N/A 291 77 [34–173] 77.7
Women <50 1,149 9 [7–43] 99.3 0 N/A N/A 0 N/A N/A
Women 50–64 448 14 [12–21] 99.2 3,246 14 [13–17] 99.0 0 N/A N/A
Women 65–74 12 N/A N/A 1,519 18 [15–21] 88.4 695 25 [17–45] 96.9
Women 75 0 N/A N/A 0 N/A N/A 485 40 [24–79] 92.7
Stratiﬁed by sex, age
(yrs), and race
Men <50, Black 445 20 [17–87] 97.4 0 N/A N/A 0 N/A N/A
Men <50, non-black 547 14 [11–17] 99.0 0 N/A N/A 0 N/A N/A
Men 50–64, black 175 28 [23–31] 91.0 389 31 [24–53] 89.7 0 N/A N/A
Men 50–64,
non-black
164 29 [12–83] 97.5 1,641 22 [19–29] 94.2 0 N/A N/A
Men 65–74, black 8 N/A N/A 119 37 [37–79] 78.2 66 35 [19–35]y 83.5
Men 65–74,
non-black
7 N/A N/A 873 30 [24–47] 89.9 338 36 [28–59] 88.3
Men 75, black 0 N/A N/A 1 N/A N/A 52 73 [26–73]y 80.5
Men 75, non-black 0 N/A N/A 0 N/A N/A 239 46 [32–71] 77.1
Women <50, black 584 15 [8–20] 99.0 0 N/A N/A 0 N/A N/A
Women <50,
non-black
565 7 [5–19] 99.4 0 N/A N/A 0 N/A N/A
Women 50–64,
black
241 13 [12–21] 99.2 837 14 [13–50] 99.0 0 N/A N/A
Women 50–64,
non-black
207 14 [9–15] 99.0 2,409 14 [13–17] 99.0 0 N/A N/A
Women 65–74,
black
7 N/A N/A 298 17 [15–21] 96.6 131 58 [15–72] 95.9
Women 65–74,
non-black
5 N/A N/A 1,221 18 [16–24] 97.5 564 24 [17–36] 97.1
Women 75, black 0 N/A N/A 0 N/A N/A 93 79 [20–79]y 91.0
Women 75,
non-black
0 N/A N/A 0 N/A N/A 392 35 [23–53] 93.0
*Subcohort 1: Subjects free from recent hospitalization (6 months), clinical cardiovascular disease (coronary heart disease, chronic heart failure, atrial ﬁbrillation, prior stroke), and stage III or greater
chronic kidney disease (estimated glomerular ﬁltration rate <60 ml/min/1.73 m2). y99th percentile is equivalent to maximum observed value.
ARIC ¼ Atherosclerosis Risk in Communities; CHS ¼ Cardiovascular Health Study; CI ¼ conﬁdence interval; DHS ¼ Dallas Health Study.
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1444The 99th percentile cut points were higher in men
compared with women, and increased in subgroups of
increasing age among both men and women. Analyses
stratiﬁed by race showed generally higher 99th percentile
values for black versus non-black individuals, particularly
among men and older women (65 years of age).
Percentiles corresponding to cTnT [ 14 ng/l. Tables 2
and 3 also include the percentiles corresponding to a
cTnT level of 14 ng/l in each subcohort and sex/age/race
stratum. These percentiles were numerically lower than the99th percentile in all overall subcohorts except subcohort
2 of DHS. Moreover, the percentile values corresponding
to 14 ng/l were consistently lower in men compared with
women, decreased with increasing age in both men and
women, and were lower in black versus non-black men and
older women.
Sensitivity analyses in the DHS study. To determine
the sensitivity of our ﬁndings to components used for the
deﬁnition of the subcohort free from clinical or subclin-
cal cardiovascular disease, we performed sensitivity analyses
Figure 1
The 99th Percentile Values for the hs-cTnT Assay in
Subcohorts 1 of the DHS, ARIC, and CHS Studies,
With Further Stratiﬁcation by Sex and Age
Subcohorts 1 include subjects free from recent hospitalization (6 months), clinical
cardiovascular disease (coronary heart disease, chronic heart failure, atrial ﬁbril-
lation, prior stroke), and stage III or greater chronic kidney disease (estimated
glomerular ﬁltration rate <60 cc/min/1.73m2). Whiskers represent 95% conﬁ-
dence intervals. ARIC ¼ Atherosclerosis Risk in Communities; CHS ¼ Cardiovas-
cular Health Study; DHS ¼ Dallas Health Study.
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1445by modifying individual exclusion criteria for DHS sub-
cohort 2, with additional stratiﬁcation by sex, race and age.
As shown in Table 4, no major differences were observed in
the 99th percentile cTnT values when the NT-proBNP
exclusion cutoff for subcohort 2 was changed from 450 to
125 ng/l, or when the NT-proBNP or electrocardiography
exclusion criteria were removed. In contrast, when exclusions
based on cardiac imaging for left ventricular hypertrophy
or left ventricular systolic dysfunction were removed, the
99th percentile values increased among men, older in-
dividuals, and black participants (Table 4).
Discussion
The key ﬁnding from this study is that a uniform upper
reference limit for the hs-cTnT assay of 14 ng/l, as currently
recommended for MI diagnosis, does not reﬂect the 99th
percentile value of a reference population with diverse
demographic characteristics. This study unequivocally de-
monstrates in a very large and well-characterized population
that 99th percentile values for the hs-cTnT assay are greater
in men and rise notably with increasing age in both men
and women. New sex- and age- speciﬁc cutoff values forthe hs-cTnT assay are proposed, and will require clinical
validation. We also found that 99th percentile values are
generally higher in black compared with non-black in-
dividuals. Although no race-speciﬁc cutoff values can be
reliably derived from the present dataset, our ﬁndings clearly
indicate that race may inﬂuence hs-cTnT assay cutoff values.
The upper reference limit for the hs-cTnT assay. By
convention, an increased cardiac troponin concentration is
deﬁned as a measurement exceeding the 99th percentile
value for the speciﬁc assay within a normal reference pop-
ulation (6,7). However, there is no consensus with regard
to the criteria for selecting a reference population, and the
deﬁnition of “normal” in this context remains a matter of
continuing debate (3,5,8).
A recent statement by the International Federation of
Clinical Chemistry and Laboratory Medicine Task Force
on Clinical Applications of Cardiac Biomarkers (3) recom-
mended that “normal” populations used to derive the 99th
percentile of high-sensitivity cardiac troponin assays should
ideally be selected by detailed physician evaluation, including
electrocardiogram, echocardiogram and NT-proBNP mea-
surement, and should include both younger and older sub-
jects. The present report is the ﬁrst to meet (and surpass)
these recommendations, far exceeding the size and thus the
statistical power of any previous study that determined the
99th percentile upper reference limit of the hs-cTnT assay.
Importantly, 99th percentile values for the hs-cTnT
assay were lower in this study when participants with sub-
clinical structural heart disease were excluded (subcohort 2),
compared with the use of less stringent exclusion criteria
(subcohort 1). These differences were magniﬁed in older
individuals, who are more likely to have subclinical car-
diovascular disease. Taken together with the results of our
sensitivity analyses, these ﬁndings support assessment of
subclinical structural heart disease to further characterize
the reference population in future studies.
The case for sex- and age-speciﬁc hs-cTnT cutoff values.
Several small studies have previously reported trends towards
higher 99th percentile values for both the hs-cTnT and hs-
cTnI assays in men (8–15) and in the elderly (9,11,14), but
small sample sizes and inconsistent phenotype character-
ization preclude the derivation of sex- and age-speciﬁc
clinical cutoff values from these studies. The most recent
update to the consensus deﬁnition of MI suggested that sex-
dependent cutoff values may be endorsed in the future for
high-sensitivity cardiac troponin assays (7), but in the
absence of reliable data, no speciﬁc numeric recommenda-
tion was made.
Based on our ﬁndings, the cutoff value for the hs-cTnT
assay should remain 14 ng/l only for men younger than
50 years of age and for women younger than 65 years of
age. Of note, the true 99th percentile cTnT value for women
younger than 50 may be lower than 14 ng/l, but validating
a lower cutoff is not feasible with the current assay because
the coefﬁcient of variation of the assay exceeds 10% at values
of 13 ng/l and lower. Utilizing the most conservative
Table 3
The 99th Percentile Value for the hs-cTnT Assay, With 95% CIs, and Percentiles Corresponding to cTnT ¼ 14 ng/l in
Subcohorts 2* of the DHS, ARIC, and CHS Studies, With Further Stratiﬁcation by Sex, Age, and Race
DHS ARIC CHS
N
99th hs-cTnT
Percentile
[95% CI] (ng/l)
Percentile for
hs-cTnT
14 ng/l N
99th hs-cTnT
Percentile
[95% CI] (ng/l)
Percentile for
hs-cTnT
14 ng/l N
99th hs-cTnT
Percentile
[95% CI] (ng/l)
Percentile for
hs-cTnT
14 ng/l
Entire subcohort 1 1,978 14 [12–17] 99.0 7,575 21 [19–22] 95.9 1,374 28 [25–35] 93.5
Stratiﬁed by sex
Men 873 17 [13–50] 98.5 2,972 26 [23–30] 91.9 489 34 [26–42] 87.4
Women 1,105 11 [7–15] 99.4 4,603 15 [14–17] 98.6 885 24 [18–35] 96.8
Stratiﬁed by sex
and age (yrs)
Men <50 651 14 [12–56] 98.8 0 N/A N/A 0 N/A N/A
Men 50–64 216 17 [14–83] 98.1 2,000 23 [21–30] 93.5 0 N/A N/A
Men 65–74 6 N/A N/A 971 31 [25–37] 88.7 297 34 [26–42] 89.5
Men 75 0 N/A N/A 1 N/A N/A 192 39 [26–39] 83.9
Women <50 790 7 [5–43] 99.4 0 N/A N/A 0 N/A N/A
Women 50–64 310 12 [11–15] 99.3 3,154 13 [13–17] 99.1 0 N/A N/A
Women 65–74 5 N/A N/A 1,449 17 [15–21] 97.6 551 24 [15–73] 97.7
Women 75 0 N/A N/A 0 N/A N/A 334 24 [18–41] 95.2
Stratiﬁed by sex, age (yrs),
and race
Men <50, black 232 23 [14–87] 97.9 0 N/A N/A 0 N/A N/A
Men <50,
non-black
419 13 [9–56] 99.3 0 N/A N/A 0 N/A N/A
Men 50–64,
black
90 21 [16–21]y 95.6 378 31 [24–53] 89.7 0 N/A N/A
Men 50–64,
non-black
126 12 [12–83] 99.2 1,622 21 [18–29] 94.5 0 N/A N/A
Men 65–74,
black
1 N/A N/A 113 37 [37–79] 78.8 50 35 [20–35]y 83.8
Men 65–74,
non-black
5 N/A N/A 858 27 [23–35] 90.1 247 32 [26–42] 90.6
Men 75, black 0 N/A N/A 1 N/A N/A 49 25 [22–25]y 81.7
Men 75,
non-black
0 N/A N/A 0 N/A N/A 153 39 [26–39] 84.4
Women <50,
black
355 6 [5–51] 99.4 0 N/A N/A 0 N/A N/A
Women <50,
non-black
435 7 [5–51] 99.5 0 N/A N/A 0 N/A N/A
Women 50–64,
Black
141 12 [11–12] N/Az 802 13 [12–49] 99.1 0 N/A N/A
Women 50–64,
non-black
169 15 [9–15] 98.8 2,352 13 [13–17] 99.1 0 N/A N/A
Women 65–74,
black
2 N/A N/A 288 17 [15–21] 96.5 114 66 [15–73] 95.3
Women 65–74,
Non-black
3 N/A N/A 1,161 17 [15–21] 97.9 437 18 [13–36] 98.3
Women 75,
black
0 N/A N/A 0 N/A N/A 70 20 [13–20]y 96.0
Women 75,
non-black
0 N/A N/A 0 N/A N/A 264 28 [18–41] 94.6
*Subcohort 2: Subjects free from recent hospitalization (6 months), clinical cardiovascular disease (coronary heart disease, chronic heart failure, atrial ﬁbrillation, prior stroke), subclinical cardiovascular
disease (left ventricular hypertrophy or left ventricular ejection fraction <55% by echo or magnetic resonance imaging, left ventricular hypertrophy by electrocardiography, N-terminal pro–B-type natriuretic
peptide >450 ng/l), and stage III or greater chronic kidney disease (estimated glomerular ﬁltration rate <60 ml/min/1.73 m2). y99th percentile is equivalent to maximum observed value. zThere was no
high-sensitivity cardiac troponin T (hs-cTnT) value 14 ng/l in this subgroup.
ARIC ¼ Atherosclerosis Risk in Communities; CHS ¼ Cardiovascular Health Study; CI ¼ conﬁdence interval; DHS ¼ Dallas Health Study.
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percentile value from multiple studies with data for sub-
cohort 2 within a given age/sex strata, as shown in Table 3),
we propose that cutoff values for the hs-cTnT assay be
increased to 17 ng/l for men 50 to 64 years of age and forwomen 65 years of age or older, and to 31 ng/l for men
65 years of age or older.
Further research is imperative to determine whether
these age- and sex-speciﬁc cutoff values improve diagnostic
performance for MI, both in prospective studies and in
Figure 2
The 99th Percentile Values for the hs-cTnT Assay in
Subcohorts 2 of the DHS, ARIC, and CHS Studies,
With Further Stratiﬁcation by Sex and Age
Subcohorts 2 include subjects free from recent hospitalization (6 months), clinical
cardiovascular disease (coronary heart disease, chronic heart failure, atrial ﬁbril-
lation, prior stroke), subclinical cardiovascular disease (left ventricular hypertrophy
or left ventricular ejection fraction <55% by echo or magnetic resonance imaging,
left ventricular hypertrophy by electrocardiography, NT-proBNP >450 pg/ml), and
stage III or greater chronic kidney disease (estimated glomerular ﬁltration
rate <60 cc/min/1.73m2). Whiskers represent 95% conﬁdence intervals. Abbre-
viations as in Figure 1.
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1447post-hoc analyses of existing databases. In addition, further
studies are necessary to determine whether age- and sex-
speciﬁc cutoffs should also be considered for hs-cTnI assays.
Study limitations. This was a retrospective study, but se-
lection bias is unlikely given the population-based nature
of the DHS, ARIC, and CHS studies. Nevertheless,Table 4
The 99th Percentile Values for the hs-cTnT Assay (ng/l) Str
Sensitivity Analyses
DHS
Subcohort 2*
Change NT-proBNP Exclusion Cutoff
From 450 to 125 ng/l
Remov
E
Overall 14 (n ¼ 1,978) 14 (n ¼ 1,872) 14 (
Men 17 (n ¼ 873) 17 (n ¼ 861) 17 (
Women 11 (n ¼ 1,105) 9 (n ¼ 1,011) 12 (
Age <50 yrs 13 (n ¼ 1,441) 13 (n ¼ 1,384) 13 (
Age 50–64 yrs 15 (n ¼ 526) 15 (n ¼ 480) 15 (
Black 16 (n ¼ 821) 16 (n ¼ 789) 16 (
Non-black 13 (n ¼ 1,157) 13 (n ¼ 1,083) 13 (
*Subcohort 2: Subjects free from recent hospitalization (6 months), clinical cardiovascular disease (coro
disease (left ventricular hypertrophy [LVH] or left ventricular ejection fraction [LVEF] <55% by magneti
[NT-proBNP] >450 ng/l), and stage III or greater chronic kidney disease (estimated glomerular ﬁltration
DHS ¼ Dallas Health Study; hs-cTnT ¼ high-sensitivity cardiac troponin T.prospective validation of the revised cutoff values proposed in
this study is critically important. Race and ethnicity were not
uniformly recorded forHispanic/Latino individuals across the
3 cohorts, and there was a low number of black individuals in
several age and race strata, thus precluding the derivation of
race-speciﬁc cutoff values for the hs-cTnT assay. Measure-
ments were performed in sample aliquots stored at –70C for a
variable amount of time, and some cTnT loss is possible with
long-term freezing (27). However, any such loss would have
led to an underestimation, not overestimation of the 99th
percentiles. Because of this potential for underestimation, our
recommendations to increase cutoff values for the hs-cTnT
assay in men and the elderly may in fact be too conservative,
and the values may be upwardly revised in the future as more
data become available. For example, a recent study of 406
consecutive patients over 70 years of age with symptoms
suggestive of acute MI reported that the optimal hs-cTnT
assay cutoff for early diagnosis of MI was 54 ng/l, as deter-
mined by receiver-operating characteristic analysis. This value
is higher than our age-speciﬁc recommendations, and is
almost 4 times higher than the presently recommended “one
size ﬁts all” upper reference limit (28).
Conclusions
More than 10% of men older than 65 years of age in our
study who were free from clinical or subclinical cardiovas-
cular disease had cTnT values above the current MI
threshold. This suggests that clinical use of the hs-cTnT
assay with the currently recommended cut point may result
in over-diagnosis of MI, particularly in elderly men.
The universal deﬁnition of MI recommends performing
serial measurements of troponins and emphasizes the im-
portance of rising and/or falling levels to distinguish acute
MI from other sources of troponin elevation (7). When
considered together with baseline levels, moderate changes
in cTnT over serial time points improve speciﬁcity for MI
with the hs-cTnT assay (29). However, it is important to
note that the operating characteristics of changes in cTnT
values are contingent on whether baseline cTnT is above the
MI detection threshold. Thus, an inaccurate upper referenceatiﬁed by Sex, Age, and Race in DHS Study Subcohort 2:
e NT-proBNP
xclusion
Remove ECG LVH
Exclusion
Remove Exclusions Based on Cardiac
Imaging for LVH or LVEF <55%
n ¼ 1,981) 14 (n ¼ 2,121) 14 (n ¼ 2,703)
n ¼ 873) 17 (n ¼ 957) 23 (n ¼ 1,205)
n ¼ 1,108) 11 (n ¼ 1,164) 11 (n ¼ 1,498)
n ¼ 1,441) 13 (n ¼ 1,538) 14 (n ¼ 1,985)
n ¼ 529) 15 (n ¼ 570) 21 (n ¼ 697)
n ¼ 823) 17 (n ¼ 931) 21 (n ¼ 1,261)
n ¼ 1,158) 13 (n ¼ 1,190) 14 (n ¼ 1,442)
nary heart disease, chronic heart failure, atrial ﬁbrillation, prior stroke), subclinical cardiovascular
c resonance imaging, LVH by electrocardiography [ECG], N-terminal pro–B-type natriuretic peptide
rate <60 ml/min/1.73 m2).
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1448limit for the hs-cTnT assay would be expected to impact
the performance of all algorithms for MI diagnosis.
Use of more accurate as well as sex- and age-speciﬁc
99th percentile values for the hs-cTnT assay would be ex-
pected to decrease false positive MI diagnosis with the
hs-cTnT assay, a problem with major clinical and public
health ramiﬁcations (30,31).
Acknowledgments
The authors thank the staff and participants of the DHS,
ARIC and CHS studies for their important contributions.
Reprint requests and correspondence: Dr. James A. de Lemos,
Department of Internal Medicine, Division of Cardiology, Uni-
versity of Texas Southwestern Medical Center, 5323 Harry Hines
Boulevard, Dallas, Texas 75390-8830. E-mail: James.deLemos@
UTSouthwestern.edu.
REFERENCES
1. Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac
troponin assays for acute coronary syndromes and the role for serial
testing. Am Heart J 2008;155:208–14.
2. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of
myocardial infarction with sensitive cardiac troponin assays. N Engl J
Med 2009;361:858–67.
3. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity
cardiac troponin assays. Clin Chem 2012;58:54–61.
4. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity
cardiac troponins in acute cardiac care. Eur Heart J 2012;33:
2252–7.
5. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity
cardiac troponin assays. J Am Coll Cardiol 2013;61:1753–8.
6. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA.
Analytical validation of a high-sensitivity cardiac troponin T assay.
Clinical Chem 2010;56:254–61.
7. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal deﬁnition of
myocardial infarction. J Am Coll Cardiol 2012;60:1581–98.
8. Collinson PO, Heung YM, Gaze D, et al. Inﬂuence of population
selection on the 99th percentile reference value for cardiac troponin
assays. Clin Chem 2012;58:219–25.
9. Saenger AK, Beyrau R, Braun S, et al. Multicenter analytical evaluation
of a high-sensitivity troponin T assay. Clin Chim Acta 2011;412:
748–54.
10. Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van
Dieijen-Visser M. Reference population and marathon runner sera
assessed by highly sensitive cardiac troponin T and commercial cardiac
troponin T and I assays. Clin Chem 2009;55:101–8.
11. Chenevier-Gobeaux C, Meune C, Blanc MC, Cynober L, Jaffray P,
Lefevre G. Analytical evaluation of a high-sensitivity troponin T assay
and its clinical assessment in acute coronary syndrome. Annals of
clinical biochemistry 2011;48:452–8.
12. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac
troponin I and T assay 99th percentile values from a common pre-
sumably healthy population. Clin Chem 2012;58:1574–81.13. Apple FS, Simpson PA, Murakami MM. Deﬁning the serum 99th
percentile in a normal reference population measured by a high-
sensitivity cardiac troponin I assay. Clin Biochem 2010;43:1034–6.
14. McKie PM, Heublein DM, Scott CG, et al. Deﬁning high-sensitivity
cardiac troponin concentrations in the community. Clin Chem 2013;
59:1099–107.
15. Keller T, Ojeda F, Zeller T, et al. Deﬁning a reference population to
determine the 99th percentile of a contemporary sensitive cardiac
troponin I assay. Int J Cardiol 2013;167:1423–9.
16. de Lemos JA, Drazner MH, Omland T, et al. Association of
troponin T detected with a highly sensitive assay and cardiac structure
and mortality risk in the general population. JAMA 2010;304:
2503–12.
17. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T
measured by a highly sensitive assay predicts coronary heart disease,
heart failure, and mortality in the Atherosclerosis Risk in Communities
Study. Circulation 2011;123:1367–76.
18. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of
serial measures of cardiac troponin T using a sensitive assay with
incident heart failure and cardiovascular mortality in older adults.
JAMA 2010;304:2494–502.
19. Victor RG, Haley RW, Willett DL, et al. The Dallas Heart Study: a
population-based probability sample for the multidisciplinary study of
ethnic differences in cardiovascular health. J Am Coll Cardiol 2004;93:
1473–80.
20. The ARIC investigators. The Atherosclerosis Risk in Communities
(ARIC) Study: design and objectives. Am J Epidemiol 1989;129:
687–702.
21. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health
Study: design and rationale. Ann Epidemiol 1991;1:263–76.
22. Troponin T hs and troponin T hs STAT product information
brochure, Elecsys 2010 System, Roche Diagnostics, 2009.
23. Hallermayer K, Jarausch J, Menassanch-Volker S, Zaugg C, Ziegler A.
Implications of adjustment of high-sensitivity cardiac troponin T assay.
Clin Chem 2013;59:572–4.
24. Apple FS, Jaffe AS. Clinical implications of a recent adjustment to the
high-sensitivity cardiac troponin T assay: user beware. Clin Chem
2012;58:1599–600.
25. Barnes SC, Collinson PO, Galasko G, Lahiri A, Senior R. Evaluation
of N-terminal pro-B type natriuretic peptide analysis on the Elecsys
1010 and 2010 analysers. Ann Clin Biochem 2004;41:459–63.
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more
accurate method to estimate glomerular ﬁltration rate from serum
creatinine: a new prediction equation. Modiﬁcation of Diet in Renal
Disease Study Group. Ann Intern Med 1999;130:461–70.
27. Basit M, Bakshi N, Hashem M, et al. The effect of freezing and long-
term storage on the stability of cardiac troponin T. Am J Clin Pathol
2007;128:164–7.
28. Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute
myocardial infarction in the elderly using more sensitive cardiac
troponin assays. Eur Heart J 2011;32:1379–89.
29. Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and
relative changes in cardiac troponin concentrations in the early diag-
nosis of acute myocardial infarction. Circulation 2011;124:136–45.
30. de Lemos JA, Morrow DA, deFilippi CR. Highly sensitive troponin
assays and the cardiology community: a love/hate relationship? Clin
Chem 2011;57:826–9.
31. de Lemos JA. Increasingly sensitive assays for cardiac troponins: a
review. JAMA 2013;309:2262–9.Key Words: diagnosis - myocardial infarction - population - troponin.
